TLX Annual Gross Profit
$204.81 M
+$139.22 M+212.28%
01 December 2023
Summary:
As of January 21, 2025, TLX annual gross profit is $204.81 million, with the most recent change of +$139.22 million (+212.28%) on December 1, 2023. During the last 3 years, it has risen by +$202.97 million (+11058.74%). TLX annual gross profit is now at all-time high.TLX Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TLX Gross Profit Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +212.3% | - | - |
3 y3 years | +10000.0% | - | - |
5 y5 years | +10000.0% | - | - |
TLX Gross Profit High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | >+9999.0% | ||||
5 y | 5-year | at high | >+9999.0% | ||||
alltime | all time | at high | >+9999.0% |
Telix Pharmaceuticals Limited Gross Profit History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2023 | $204.81 M(+212.3%) | - | - |
Dec 2022 | $65.58 M(+3616.5%) | - | - |
Dec 2021 | $1.76 M(-3.9%) | - | - |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2020 | $1.84 M(+180.3%) | - | - |
Dec 2019 | $654.90 K(+349.5%) | - | - |
Dec 2018 | $145.70 K | - | - |
FAQ
- What is Telix Pharmaceuticals Limited annual gross profit?
- What is the all time high annual gross profit for Telix Pharmaceuticals Limited?
- What is Telix Pharmaceuticals Limited annual gross profit year-on-year change?
What is Telix Pharmaceuticals Limited annual gross profit?
The current annual gross profit of TLX is $204.81 M
What is the all time high annual gross profit for Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited all-time high annual gross profit is $204.81 M
What is Telix Pharmaceuticals Limited annual gross profit year-on-year change?
Over the past year, TLX annual gross profit has changed by +$139.22 M (+212.28%)